PE20212267A1 - Nuevas capsides de aav y composiciones que las contienen - Google Patents
Nuevas capsides de aav y composiciones que las contienenInfo
- Publication number
- PE20212267A1 PE20212267A1 PE2021001795A PE2021001795A PE20212267A1 PE 20212267 A1 PE20212267 A1 PE 20212267A1 PE 2021001795 A PE2021001795 A PE 2021001795A PE 2021001795 A PE2021001795 A PE 2021001795A PE 20212267 A1 PE20212267 A1 PE 20212267A1
- Authority
- PE
- Peru
- Prior art keywords
- novel aav
- compositions containing
- capsides
- aav capsides
- novel
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title 1
- 210000000234 capsid Anatomy 0.000 abstract 2
- 230000026683 transduction Effects 0.000 abstract 1
- 238000010361 transduction Methods 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/0075—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the delivery route, e.g. oral, subcutaneous
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14142—Use of virus, viral particle or viral elements as a vector virus or viral particle as vehicle, e.g. encapsulating small organic molecule
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14151—Methods of production or purification of viral material
- C12N2750/14152—Methods of production or purification of viral material relating to complementing cells and packaging systems for producing virus or viral particles
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Biomedical Technology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Gastroenterology & Hepatology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962840184P | 2019-04-29 | 2019-04-29 | |
| US201962913314P | 2019-10-10 | 2019-10-10 | |
| US201962924095P | 2019-10-21 | 2019-10-21 | |
| PCT/US2020/030281 WO2020223236A1 (en) | 2019-04-29 | 2020-04-28 | Novel aav capsids and compositions containing same |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20212267A1 true PE20212267A1 (es) | 2021-11-30 |
Family
ID=73028724
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001795A PE20212267A1 (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen |
| PE2021001788A PE20220014A1 (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen |
| PE2021001789A PE20212334A1 (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2021001788A PE20220014A1 (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen |
| PE2021001789A PE20212334A1 (es) | 2019-04-29 | 2020-04-28 | Nuevas capsides de aav y composiciones que las contienen |
Country Status (16)
| Country | Link |
|---|---|
| US (3) | US12516351B2 (enExample) |
| EP (3) | EP3976078A4 (enExample) |
| JP (3) | JP7644026B2 (enExample) |
| KR (3) | KR20220004680A (enExample) |
| CN (3) | CN113853208A (enExample) |
| AU (3) | AU2020266523A1 (enExample) |
| BR (3) | BR112021021502A2 (enExample) |
| CA (3) | CA3134379A1 (enExample) |
| CL (3) | CL2021002768A1 (enExample) |
| CO (3) | CO2021015928A2 (enExample) |
| IL (3) | IL287491A (enExample) |
| MX (3) | MX2021013266A (enExample) |
| PE (3) | PE20212267A1 (enExample) |
| PH (3) | PH12021552608A1 (enExample) |
| SG (3) | SG11202111373YA (enExample) |
| WO (3) | WO2020223232A1 (enExample) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL293972A (en) | 2019-12-19 | 2022-08-01 | Univ Pennsylvania | Preparations for the treatment of Friedrich's ataxia |
| JP2023531451A (ja) | 2020-06-17 | 2023-07-24 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 遺伝子療法患者の治療のための組成物及び方法 |
| BR112023003310A2 (pt) | 2020-08-24 | 2023-05-02 | Univ Pennsylvania | Vetores virais que codificam fusões de agonistas do receptor de glp-1 e usos dos mesmos no tratamento de doenças metabólicas |
| WO2022094078A1 (en) | 2020-10-28 | 2022-05-05 | The Trustees Of The University Of Pennsylvania | Compositions useful in treatment of rett syndrome |
| CA3201533A1 (en) | 2020-11-11 | 2022-05-19 | European Molecular Biology Laboratory | Modified viral particles for gene therapy |
| MX2023006445A (es) * | 2020-12-01 | 2023-08-10 | Univ Pennsylvania | Composiciones y usos de estas para el tratamiento del síndrome de angelman. |
| AR124216A1 (es) | 2020-12-01 | 2023-03-01 | Univ Pennsylvania | Composiciones nuevas con motivos selectivos específicos del tejido y composiciones que las contienen |
| MX2023012513A (es) | 2021-04-23 | 2023-12-15 | Univ Pennsylvania | Nuevas composiciones con motivos selectivos para el cerebro y composiciones que las contienen. |
| WO2023147304A1 (en) | 2022-01-25 | 2023-08-03 | The Trustees Of The University Of Pennsylvania | Aav capsids for improved heart transduction and detargeting of liver |
| KR20240167720A (ko) * | 2022-03-01 | 2024-11-27 | 더 트러스티스 오브 더 유니버시티 오브 펜실베니아 | 인슐린 융합 단백질을 암호화하는 바이러스 벡터 게놈 |
| JP2025508988A (ja) * | 2022-03-03 | 2025-04-10 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | 副甲状腺ホルモン融合物をコードするウイルスベクター及び副甲状腺機能低下症の治療におけるその使用 |
| WO2023196893A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treating her2 positive metastatic breast cancer and other cancers |
| WO2023196892A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti- aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
| US20260021205A1 (en) * | 2022-07-15 | 2026-01-22 | The Trustees Of The University Of Pennsylvania | Recombinant aav having aav clade d and clade e capsids and compositions containing same |
| WO2024130067A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav mutant vectors with cardiac and skeletal muscle-specific targeting motifs and compositions containing same |
| WO2024130070A2 (en) | 2022-12-17 | 2024-06-20 | The Trustees Of The University Of Pennsylvania | Recombinant aav capsids with cardiac- and skeletal muscle- specific targeting motifs and uses thereof |
| EP4724085A1 (en) | 2023-06-12 | 2026-04-15 | The Trustees of The University of Pennsylvania | Aav gene therapy for mucopolysaccharidosis iiib |
| AR133098A1 (es) | 2023-06-29 | 2025-08-27 | Univ Pennsylvania | Aav mutante con motivos dirigidos al sistema nervioso central y composiciones que lo contienen |
| WO2025035143A1 (en) | 2023-08-10 | 2025-02-13 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of spinal muscular atrophy |
| WO2025102034A1 (en) | 2023-11-10 | 2025-05-15 | The Trustees Of The University Of Pennsylvania | Gene therapy for barth syndrome |
| WO2025106661A1 (en) | 2023-11-14 | 2025-05-22 | The Trustees Of The University Of Pennsylvania | Compositions with cardiac and skeletal musclespecific targeting motifs and uses thereof |
| GB202319008D0 (en) * | 2023-12-13 | 2024-01-24 | Ucl Business Ltd | AAV-mediated gene therapy of diseases caused by impaired function of GLDC |
| WO2025129157A1 (en) | 2023-12-15 | 2025-06-19 | The Trustees Of The University Of Pennsylvania | Gene therapy for treatment of canavan disease |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5478745A (en) | 1992-12-04 | 1995-12-26 | University Of Pittsburgh | Recombinant viral vector system |
| US6156303A (en) | 1997-06-11 | 2000-12-05 | University Of Washington | Adeno-associated virus (AAV) isolates and AAV vectors derived therefrom |
| US6221349B1 (en) | 1998-10-20 | 2001-04-24 | Avigen, Inc. | Adeno-associated vectors for expression of factor VIII by target cells |
| US6200560B1 (en) | 1998-10-20 | 2001-03-13 | Avigen, Inc. | Adeno-associated virus vectors for expression of factor VIII by target cells |
| SG10202108118RA (en) | 2001-11-13 | 2021-08-30 | Univ Pennsylvania | A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby |
| ES2975413T3 (es) | 2001-12-17 | 2024-07-05 | Univ Pennsylvania | Secuencias de serotipo 8 de virus adenoasociado (AAV), vectores que las contienen y usos de las mismas |
| EP1486567A1 (en) | 2003-06-11 | 2004-12-15 | Deutsches Krebsforschungszentrum Stiftung des öffentlichen Rechts | Improved adeno-associated virus (AAV) vector for gene therapy |
| US8005620B2 (en) | 2003-08-01 | 2011-08-23 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| WO2005013090A2 (en) | 2003-08-01 | 2005-02-10 | Dna Twopointo Inc. | Systems and methods for biopolymer engineering |
| HUE054805T2 (hu) * | 2003-09-30 | 2021-09-28 | Univ Pennsylvania | Adeno-asszociált vírus (AAV) kládok, szekvenciák, az azokat tartalmazó vektorok és alkalmazásaik |
| EP3085389A1 (en) * | 2005-04-07 | 2016-10-26 | The Trustees Of The University Of Pennsylvania | Method of increasing the function of an aav vector |
| US8283151B2 (en) * | 2005-04-29 | 2012-10-09 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Isolation, cloning and characterization of new adeno-associated virus (AAV) serotypes |
| CN101495624A (zh) * | 2006-04-28 | 2009-07-29 | 宾夕法尼亚州立大学托管会 | 衣壳免疫原性降低的经修饰aav载体及其用途 |
| EP2012122A1 (en) | 2007-07-06 | 2009-01-07 | Medigene AG | Mutated parvovirus structural proteins as vaccines |
| WO2009137006A2 (en) | 2008-04-30 | 2009-11-12 | The University Of North Carolina At Chapel Hill | Directed evolution and in vivo panning of virus vectors |
| WO2010138263A2 (en) * | 2009-05-28 | 2010-12-02 | University Of Massachusetts | Novel aav 's and uses thereof |
| EP2287323A1 (en) | 2009-07-31 | 2011-02-23 | Association Institut de Myologie | Widespread gene delivery to the retina using systemic administration of AAV vectors |
| KR20130040844A (ko) | 2010-03-29 | 2013-04-24 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 약학적으로 유발된 전이유전자 제거 시스템 |
| US9315825B2 (en) | 2010-03-29 | 2016-04-19 | The Trustees Of The University Of Pennsylvania | Pharmacologically induced transgene ablation system |
| EP3567106A1 (en) | 2010-04-23 | 2019-11-13 | University of Massachusetts | Cns targeting aav vectors and methods of use thereof |
| WO2013155222A2 (en) | 2012-04-10 | 2013-10-17 | The Regents Of The University Of California | Brain-specific enhancers for cell-based therapy |
| WO2015012924A2 (en) | 2013-04-29 | 2015-01-29 | The Trustees Of The University Of Pennsylvania | Tissue preferential codon modified expression cassettes, vectors containing same, and use thereof |
| PT3024498T (pt) * | 2013-07-22 | 2020-03-06 | Childrens Hospital Philadelphia | Variante aav e composições, métodos e usos para transferência genética em células, órgãos e tecidos |
| NZ718926A (en) * | 2013-10-11 | 2021-12-24 | Massachusetts Eye & Ear Infirmary | Methods of predicting ancestral virus sequences and uses thereof |
| EP4450630A3 (en) | 2014-03-10 | 2025-01-29 | uniQure IP B.V. | Further improved aav vectors produced in insect cells |
| US10577627B2 (en) * | 2014-06-09 | 2020-03-03 | Voyager Therapeutics, Inc. | Chimeric capsids |
| RU2020140209A (ru) * | 2014-10-21 | 2021-01-25 | Юниверсити Оф Массачусетс | Варианты рекомбинантных aav и их применения |
| EP4344741A3 (en) * | 2014-11-21 | 2024-08-28 | The University of North Carolina at Chapel Hill | Aav vectors targeted to the central nervous system |
| US10876134B2 (en) * | 2014-12-16 | 2020-12-29 | Board Of Regents Of The University Of Nebraska | Gene therapy for juvenile batten disease |
| US20180021364A1 (en) | 2015-01-16 | 2018-01-25 | Voyager Therapeutics, Inc. | Central nervous system targeting polynucleotides |
| JP6851319B2 (ja) | 2015-04-27 | 2021-03-31 | ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア | ヒト疾患のＣＲＩＳＰＲ／Ｃａｓ９媒介性の修正のためのデュアルＡＡＶベクター系 |
| EP4134375A1 (en) | 2015-07-30 | 2023-02-15 | Massachusetts Eye & Ear Infirmary | Ancestral adeno associated virus sequences and uses thereof |
| EP3368054A4 (en) | 2015-10-28 | 2019-07-03 | Voyager Therapeutics, Inc. | REGULATORY EXPRESSION USING THE ADENO-ASSOCIATED VIRUS (AAV) |
| WO2017075338A2 (en) * | 2015-10-29 | 2017-05-04 | Voyager Therapeutics, Inc. | Delivery of central nervous system targeting polynucleotides |
| US11326182B2 (en) | 2016-04-29 | 2022-05-10 | Voyager Therapeutics, Inc. | Compositions for the treatment of disease |
| SG11201809699XA (en) | 2016-05-18 | 2018-12-28 | Voyager Therapeutics Inc | Modulatory polynucleotides |
| CA3040179A1 (en) * | 2016-10-19 | 2018-04-26 | Adverum Biotechnologies, Inc. | Modified aav capsids and uses thereof |
| MX2019010275A (es) * | 2017-02-28 | 2019-10-15 | Univ Pennsylvania | Novedoso vector del subtipo f del virus adenoasociado (aav) y usos de este. |
| IL316259A (en) | 2017-03-15 | 2024-12-01 | Univ North Carolina Chapel Hill | Polyploid gland associated with virus vectors and methods for preparing and using the same. |
| US10550405B2 (en) | 2017-03-15 | 2020-02-04 | The University Of North Carolina At Chapel Hill | Rational polyploid adeno-associated virus vectors and methods of making and using the same |
| WO2018200419A1 (en) * | 2017-04-23 | 2018-11-01 | The Trustees Of The University Of Pennsylvania | Viral vectors comprising engineered aav capsids and compositions containing the same |
| JOP20190269A1 (ar) | 2017-06-15 | 2019-11-20 | Voyager Therapeutics Inc | بولي نوكليوتيدات aadc لعلاج مرض باركنسون |
| TWI832036B (zh) * | 2017-08-03 | 2024-02-11 | 美商航海家醫療公司 | 用於aav之遞送之組合物及方法 |
| AU2018350992A1 (en) | 2017-10-18 | 2020-05-21 | Regenxbio Inc. | Fully-human post-translationally modified antibody therapeutics |
| IL276859B2 (en) | 2018-02-27 | 2025-12-01 | Univ Pennsylvania | Novel adeno-associated virus (aav) vectors, aav vectors having reduced capsid deamidation and uses therefor |
| AU2019228504B2 (en) | 2018-02-27 | 2025-06-26 | The Trustees Of The University Of Pennsylvania | Novel adeno-associated virus (AAV) vectors, AAV vectors having reduced capsid deamidation and uses therefor |
| CA3123600A1 (en) | 2018-12-21 | 2020-06-25 | The Trustees Of The University Of Pennsylvania | Compositions for drg-specific reduction of transgene expression |
-
2020
- 2020-04-28 MX MX2021013266A patent/MX2021013266A/es unknown
- 2020-04-28 JP JP2021564542A patent/JP7644026B2/ja active Active
- 2020-04-28 PH PH1/2021/552608A patent/PH12021552608A1/en unknown
- 2020-04-28 BR BR112021021502A patent/BR112021021502A2/pt unknown
- 2020-04-28 MX MX2021013267A patent/MX2021013267A/es unknown
- 2020-04-28 JP JP2021564543A patent/JP2022530656A/ja active Pending
- 2020-04-28 EP EP20798752.0A patent/EP3976078A4/en active Pending
- 2020-04-28 US US17/605,868 patent/US12516351B2/en active Active
- 2020-04-28 KR KR1020217037659A patent/KR20220004680A/ko not_active Withdrawn
- 2020-04-28 KR KR1020217037661A patent/KR20220004681A/ko active Pending
- 2020-04-28 WO PCT/US2020/030273 patent/WO2020223232A1/en not_active Ceased
- 2020-04-28 BR BR112021020545A patent/BR112021020545A2/pt unknown
- 2020-04-28 BR BR112021020054A patent/BR112021020054A2/pt unknown
- 2020-04-28 CA CA3134379A patent/CA3134379A1/en active Pending
- 2020-04-28 SG SG11202111373YA patent/SG11202111373YA/en unknown
- 2020-04-28 WO PCT/US2020/030266 patent/WO2020223231A1/en not_active Ceased
- 2020-04-28 SG SG11202111375RA patent/SG11202111375RA/en unknown
- 2020-04-28 EP EP20798753.8A patent/EP3962507A4/en not_active Withdrawn
- 2020-04-28 CA CA3134468A patent/CA3134468A1/en active Pending
- 2020-04-28 CA CA3134507A patent/CA3134507A1/en active Pending
- 2020-04-28 PH PH1/2021/552540A patent/PH12021552540A1/en unknown
- 2020-04-28 PE PE2021001795A patent/PE20212267A1/es unknown
- 2020-04-28 US US17/605,874 patent/US12516352B2/en active Active
- 2020-04-28 EP EP20798442.8A patent/EP3976077A4/en active Pending
- 2020-04-28 CN CN202080032773.1A patent/CN113853208A/zh active Pending
- 2020-04-28 AU AU2020266523A patent/AU2020266523A1/en active Pending
- 2020-04-28 AU AU2020264976A patent/AU2020264976A1/en active Pending
- 2020-04-28 PE PE2021001788A patent/PE20220014A1/es unknown
- 2020-04-28 PH PH1/2021/552607A patent/PH12021552607A1/en unknown
- 2020-04-28 SG SG11202111102SA patent/SG11202111102SA/en unknown
- 2020-04-28 PE PE2021001789A patent/PE20212334A1/es unknown
- 2020-04-28 KR KR1020217038207A patent/KR20220004695A/ko active Pending
- 2020-04-28 AU AU2020264975A patent/AU2020264975A1/en active Pending
- 2020-04-28 CN CN202080033196.8A patent/CN113853209B/zh active Active
- 2020-04-28 WO PCT/US2020/030281 patent/WO2020223236A1/en not_active Ceased
- 2020-04-28 CN CN202080032666.9A patent/CN113853207A/zh active Pending
- 2020-04-28 US US17/605,881 patent/US20220249705A1/en not_active Abandoned
- 2020-04-28 JP JP2021564269A patent/JP7690401B2/ja active Active
- 2020-04-28 MX MX2021013268A patent/MX2021013268A/es unknown
-
2021
- 2021-10-21 IL IL287491A patent/IL287491A/en unknown
- 2021-10-21 IL IL287492A patent/IL287492A/en unknown
- 2021-10-21 CL CL2021002768A patent/CL2021002768A1/es unknown
- 2021-10-21 IL IL287498A patent/IL287498A/en unknown
- 2021-10-26 CL CL2021002811A patent/CL2021002811A1/es unknown
- 2021-10-27 CL CL2021002824A patent/CL2021002824A1/es unknown
- 2021-11-25 CO CONC2021/0015928A patent/CO2021015928A2/es unknown
- 2021-11-25 CO CONC2021/0015916A patent/CO2021015916A2/es unknown
- 2021-11-25 CO CONC2021/0015924A patent/CO2021015924A2/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CO2021015924A2 (es) | Nuevas cápsides de aav y composiciones que las contienen | |
| MX2023001863A (es) | Nuevas cápsides de aav y composiciones que las contienen. | |
| BR112023022318A2 (pt) | Capsídeos de aav e seu uso | |
| PE20210915A1 (es) | Capsides variantes de virus adenoasociados y su uso para inhibir la angiogenesis | |
| MX2019009720A (es) | Metodos y composiciones para la transferencia de genes a traves de la vasculatura. | |
| EP3917566A4 (en) | METHODS OF USING TRANSCRIPTION-DEPENDENT DIRECTED EVOLUTION OF AAV CAPSIDS | |
| CL2019000167A1 (es) | Novedosas proteínas de la cápside del virus adenoasociado. | |
| CL2023001793A1 (es) | Anticuerpos anti-componente de complemento y métodos de uso | |
| MX2025015023A (es) | Variantes de capsides de aav para liberacion intravitrea | |
| UY38003A (es) | Construcciones de arni para inhibir la expresión de pnpla3 y métodos de uso de las mismas | |
| PE20150163A1 (es) | Composicion y metodos para una transferencia de genes altamente eficiente usando variantes capside aav | |
| CL2021002236A1 (es) | Inserción de vectores de virus adeno-asociados de b-sarcoglicano y el tratamiento de distrofia muscular | |
| UY37863A (es) | Virus adenoasociado (aav) con dominio de fosfolipasa modificado | |
| EP4019642A4 (en) | Isolated modified vp1 capsid protein of aav5 | |
| UY37376A (es) | Construcciones de arni para inhibir expresión de asgr1 y métodos para su uso | |
| UY38733A (es) | Construcciones de arni para inhibir la expresión de scap y métodos de uso de las mismas | |
| MX2024009186A (es) | Cápsides de aav para mejorar la transducción cardiaca y desdireccionamiento del hígado. | |
| AR120259A1 (es) | Variantes de aav3b con rendimiento mejorado de la producción y tropismo hepático | |
| MX2022001639A (es) | Extracto de aquenios de silybum marianum (l.) gaertn. para promover el crecimiento del cabello. | |
| EA202192955A1 (ru) | Новые капсиды aav и композиции, содержащие их | |
| EP4389760A4 (en) | AAV9 CAPSIDE VP1 MODIFIED PROTEIN | |
| EP3984549A4 (en) | Medicinal composition | |
| EP4010041A4 (en) | Steam sterilization of hydrogels crosslinked by beta-eliminative linkers | |
| BR112021025865A2 (pt) | Hidróxi-isoxazolinas e derivados das mesmas | |
| BR112021025305A2 (pt) | Hidroxi-isoxazolinas e uso das mesmas como fungicidas |